Sean O'Shaughnessey on May 23rd, 2015
Share on StockTwits
Share

 

berkshirehathawayinfographic-finalrevised

Share

Tags:

Please read the disclaimer before using any information on this site.

To learn how to retire with enough money to live in luxury during your retirement and enjoy the good life, download the free whitepaper Retire In Luxury
Sean O'Shaughnessey on May 23rd, 2015
Share on StockTwits
Share

This information was calculated on May 23, 2015 and is based on the closing value of the most recent trading day which may not be today.

This information is based on the Yahoo Historical Pricing and is only as good or as current as that data Click here to read the rest of this article

Share
Please read the disclaimer before using any information on this site.

To learn how to retire with enough money to live in luxury during your retirement and enjoy the good life, download the free whitepaper Retire In Luxury
Sean O'Shaughnessey on May 22nd, 2015
Share on StockTwits
Share

This information was calculated on May 22, 2015 and is based on the closing value of the most recent trading day which may not be today.

This information is based on the Yahoo Historical Pricing and is only as good or as current as that data Click here to read the rest of this article

Share
Please read the disclaimer before using any information on this site.

To learn how to retire with enough money to live in luxury during your retirement and enjoy the good life, download the free whitepaper Retire In Luxury
Sean O'Shaughnessey on May 21st, 2015
Share on StockTwits
Share

Investors certainly have to be happy with Zebra Technologies Corp. (ZBRA: 109.65 +0.31 +0.28%) and its short term performance. After all, the stock has jumped by 13.5% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for ZBRA?

While we can never know for sure, it is pretty encouraging that estimates for ZBRA have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks.

Source: Can The Uptrend Continue for Zebra Technologies (ZBRA)? - May 19, 2015 - Zacks.com

Share

Tags:

Please read the disclaimer before using any information on this site.

To learn how to retire with enough money to live in luxury during your retirement and enjoy the good life, download the free whitepaper Retire In Luxury
Sean O'Shaughnessey on May 21st, 2015
Share on StockTwits
Share

This information was calculated on May 21, 2015 and is based on the closing value of the most recent trading day which may not be today.

This information is based on the Yahoo Historical Pricing and is only as good or as current as that data Click here to read the rest of this article

Share
Please read the disclaimer before using any information on this site.

To learn how to retire with enough money to live in luxury during your retirement and enjoy the good life, download the free whitepaper Retire In Luxury
Sean O'Shaughnessey on May 20th, 2015
Share on StockTwits
Share

This information was calculated on May 20, 2015 and is based on the closing value of the most recent trading day which may not be today.

This information is based on the Yahoo Historical Pricing and is only as good or as current as that data Click here to read the rest of this article

Share
Please read the disclaimer before using any information on this site.

To learn how to retire with enough money to live in luxury during your retirement and enjoy the good life, download the free whitepaper Retire In Luxury
Sean O'Shaughnessey on May 20th, 2015
Share on StockTwits
Share

The German company is pinning its health care hopes on successfully developing its anti-PDL1 immuno-oncology treatment in alliance with Pfizer. That puts the pharmaceutical and materials company in one of the hottest, but also most competitive, areas in health care. And Merck doesn’t have an obvious edge.

Merck’s (MRK: 59.38 -0.72 -1.20%) first-quarter results Tuesday showed its challenges. Its biggest product, multiple sclerosis drug Rebif is in decline: sales excluding currency movements fell 15.9% in the first quarter from a year earlier, though still accounted for a quarter of Merck’s health care revenues.

Merck has been bulking up in more stable, higher-growth areas with last year’s acquisition of AZ Electronic Materials and its yet-to-close €13.1 billion deal to buy Sigma-Aldrich, the maker of life sciences tools.

At the same time, it is ramping up research and development spending to try to take on more advanced rivals like Bristol-Myers Squibb, Merck & Co. of the U.S., Roche and AstraZeneca in immuno-oncology. Up to 20 development programs could start this year, six of which could form the basis of a registration with U.S. regulators.

Source: Merck Could Struggle to Hit Health Care Heights

Share

Tags:

Please read the disclaimer before using any information on this site.

To learn how to retire with enough money to live in luxury during your retirement and enjoy the good life, download the free whitepaper Retire In Luxury